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Abstract: Glioblastoma multiforme (GBM), the most common form of primary brain tumor, 
is highly resistant to current treatment paradigms and has a high rate of recurrence. Recent 
advances in the field of tumor-initiating cells suggest that glioblastoma stem cells (GSCs) 
may be responsible for GBM’s rapid progression, treatment resistance, tumor recurrence and 
ultimately poor clinical prognosis. Understanding the biologically significant pathways that 
mediate GSC-specific characteristics offers promises in the development of novel 
biomarkers and therapeutics. Long non-coding RNAs (lncRNAs) have been increasingly 
implicated in the regulation of cancer cell biological behavior through various mechanisms. 
Initial studies strongly suggested that lncRNA expressions are highly dysregulated in GSCs 
and may play important roles in determining malignant phenotypes in GBM. Here, we 
review available evidence on aberrantly expressed lncRNAs identified by high throughput 
microarray profiling studies in GSCs. We also explore the potential functional pathways by 
analyzing their interactive proteins and miRNAs, with a view to shed lights on how this 
novel class of molecular candidates may mediate GSC maintenance and differentiation. 
Keywords: glioblastoma stem cell; lncRNA; transcription factor; miRNA; lncRNA-protein 
interaction; lncRNA-miRNA interaction; signal pathway 
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1. Introduction 
An important progress in cancer biology has been the identification of a key subpopulation of  
tumor cells with stem cell properties, now commonly referred to as cancer stem cells (CSCs) [1,2]. The 
latter make up only a small fraction of the tumor cell mass, but are thought to be able to self-renew and 
re-generate the parent tumor [1–4]. Glioblastoma multiforme (GBM), the most common and deadly 
malignant primary brain tumor, was among the first solid tumors in which the existence of CSCs was 
experimentally demonstrated about a decade ago [5–7]. Currently, glioblastoma stem cells (GSCs) have 
been extensively validated in various preclinical models and characterized as the tumor-initiating cells 
of GBM, as well as the potential reason for the tumor’s innate radio-chemo resistance [8–14]. These 
findings provided an impetus for furthering our understanding of the cellular and molecular mechanisms 
of tumor maintenance and recurrence in GBM. 
Long non-coding RNAs (lncRNAs), which are by definition transcripts with lengths greater than  
200 nucleotides and without protein-coding function, have been proposed as key regulators of diverse 
biological processes including cell pluripotency and tumorigenesis [15–18]. They are aberrantly 
expressed in a variety of diseases, and may mechanistically interact with key proteins or RNAs to execute 
their biological functions at various levels [16,18,19]. Increasing evidence shows that abnormal 
expression of lncRNAs may alter basic cellular biological processes and contribute to the malignant  
phenotypes in GBM [20–24]. Moreover, differential expression of specific lncRNAs may also correlate 
with the tumorigenic properties of GSCs [25]. 
In this review, we summarize currently available evidence regarding the potential associations 
between lncRNAs and GSCs. First, we review the current knowledge about the definitions, 
characteristics and biomarkers of GSCs. Second, we provide a comprehensive summary of known 
lncRNA dysregulations in GSCs by screening existing microarray gene expression data. Finally, we 
discuss the potential functions and mechanisms of these lncRNAs in GSC maintenance and 
differentiation by analyzing the formers’ interactive transcription factors (TFs), miRNAs as well as RNA 
binding proteins (RBPs). 
2. GSCs-Definitions, Characteristics and Biomarkers 
Despite continued efforts, there is as yet no consensus within the scientific community on how  
to define CSCs and thus GSCs. According to the American Association of Cancer Research (AACR) 
workshop, CSCs are a subpopulation of cells that have the capacities for self-renewal and differentiation 
into heterogeneous subpopulations of cancer cells that comprise the tumor [26]. To be identified as 
GSCs, therefore, glioblastoma cells must possess the ability of sustainable neurosphere formation in 
culture and tumor generation in vivo (self-renewal), as well as the ability to differentiate into multiple 
neural lineages that recapitulate the initiate tumor pathology (multiple differentiation) [27,28]. From a 
clinical point of view, GSCs are thought of as the small fraction of malignant cells that may survive 
conventional chemo-and radiotherapy, and regenerate recurrent tumors [12,29,30] (Figure 1). 
While there has been considerable interest in studying CSCs derived from GBM tissues, isolating this 
sparse population of cells with high yield and viability from tumor bulks has been a challenge. These 
cells have been isolated in serum-lacking media containing growth factors, and would aggregate into 
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spheres in suspension [5–7]. The main advantage of the serum-lacking culture method is the greater 
preservation of native phenotypes and genotypes, which are less well preserved in cells cultured in 
serum-containing medium because of the accumulation of aberrations over repeated passaging [31]. In 
contrast to the hyper-proliferative and hyper-angiogenic phenotypes of glioblastoma tumors, GSCs 
possess neuroectodermal properties, and express genes associated with neural stem cells, radial glial cells 
and neural crest cells, while portraying also a migratory, quiescent and undifferentiated phenotype [32]. 
Thus, cell-cycle-targeted radio-chemotherapy, which aims to kill fast-growing tumor cells, would not 
completely eliminate GBM tumors [32]. 
 
Figure 1. Cancer stem cell theory. 
GSCs have biomarkers that are distinct from those found in differentiated tumor cells, and the 
isolation of GSCs based on surface markers is now feasible [33]. Currently, a subset of identifiable 
surface markers, summarized in several comprehensive reviews [14,28,34,35], has been used to isolate 
and characterize GSCs even though their specificities remain controversial. These include CD133, 
A2B5, Musashi-1 and Nestin. Amongst these, CD133, also referred to prominin-1, is the most widely 
studied and employed marker for GSCs. CD133 is a trans-membrane protein with no clearly-defined 
function [36,37]. Multiple independent studies found that CD133 + GBM cells fulfilled the definition of 
GSCs in that they had higher colony formation efficiency, multilineage differentiation capacity, and an 
increased ability to form tumors in serially transplantable xenografts when compared to CD133 − GBM 
cells [5,6,30,32,38,39]. However, subsequent studies revealed that CD133 did not consistently 
distinguish GSCs from non-GSCs, and CD133− cells may also be tumorigenic when xenografted  
in vivo [40,41]. These discrepancies illustrate the potential heterogeneity of GSCs as well as the necessity 
to employ combined markers or methods (such as functional identification) in enriching and validating 
GSC populations. 
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3. LncRNAs Dysregulated in GSCs 
The distinct growth behaviors and characteristics of GSCs mean that it is intellectually attractive and 
clinically relevant to identify the underlying molecular characteristics, which may provide new insights 
into the elimination of this subpopulation of cells and provide curative strategies. Previous genome-wide 
profiling studies have identified aberrantly expressed protein-coding genes and miRNA genes associated 
with GSCs [39–42]. In contrast, dysregulation of lncRNAs in GSCs at individual gene levels have not 
been reported until recently; the global and comprehensive lncRNA transcriptome features in GSCs 
remain largely unknown. Our previous studies and several other independent studies showed that 
lncRNA profiling could actually be achieved by mining the existing microarray gene data, such as the 
Affymetrix microarray datasets [43–46]. Based on this approach, the dysregulated lncRNAs associated 
with GSC properties are comprehensively screened and summarized in this present review. The published 
GSC microarray gene expression study (on Affymetrix HG U133 Plus 2.0 platform) used for lncRNA 
mining here, as well as the dysregulated lncRNAs identified from them, are summarized in Table 1. 
Table 1. Published GSC profiling studies as well as the dysregulated lncRNAs identified. 
Authors 1 Year Samples 
No. of No. of 
Ref. 
Up-regulated LncRNAs (≥2.0 fold) 2 Down-regulated LncRNAs (≥2.0 fold) 2 
Dysregulated LncRNAs between GSCs and Differentiated GBM Cells Comparison 
Araki et al. 2013 
GSC (sphere) vs. 
differentiated  
GBM cells 
6: LOC100127888, H19,  
RP11-112J3.16, et al. 
28: DLX6-AS, LOC643763,  
FLJ39609, et al. 
[47] 
Aldaz et al. 2013 
GSC (sphere) vs. 
differentiated  
GBM cells 
28: H19, MIAT, LOC150622, 
LOC100127888, XIST,  
RP11-112J3.16, et al. 
11: RP11-346D6.6, C6orf155, HCG4, 
FLJ39609, et al. 
[42] 
Dysregulated LncRNAs between GSCs with Different Subtypes 
Beier et al. 2007 
CD133 + GSCs 
vs. CD133 − 
GSCs 
38: XIST, H19, HOTAIR, LOC100192378, 
AC006213.1, MIAT, et al. 
34: CTC-231O11.1, RP11-745C15.2, 
LOC100130776, C14orf139, et al. 
[40] 
Gunther et al. 2008 
CD133+ GSCs vs. 
CD133 − GSCs 
51: H19, RP11-331K15.1, RP11-547I7.2, 
LOC100192378, MIAT, HOTAIR, et al. 
10: C14orf139, DLX6-AS, MIR155HG, 
LOC100130776, et al. 
[41] 
Dysregulated LncRNAs between GSCs and NSCs Comparison 
Rheinbay, et al. 2013 GSCs vs. NSCs 
173: LOC399959, LOC645323, 
HOTAIRM1, H19, MALAT1, SOX2ot,  
et al.  
19: HYMAI, AL133167.1,  
FLJ31485, et al. 
[58] 
1 Profiling studies searching was performed in public GEO database (December, 2014). Only the datasets 
profiled on Affymetrix HG-U133 Plus 2.0 microarray platform were enrolled in our review analysis. With 
regard to how to process Affymetrix HG-U133 Plus 2.0 raw data and mine lncRNA information from it, please 
refer to our previous paper for details [43]. 2 For each individual study reviewed here, the total number of 
dysregulated lncRNAs, as well as the representative candidates were listed. Representative candidates were 
defined if they fulfilled one of following the criteria: (1) They were the top 3 dysregulated genes in comparison; 
(2) They appeared in more than one independent study reviewed at the same dysregulation pattern; (3) They 
have been functionally reported in public studies, especially in cancer. 
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3.1. Dysregulated LncRNAs during GSC Differentiation 
Comparative analyses of lncRNA expression profiles in GSCs (defined by sphere formation) and their 
differentiated tumor cell counterparts (induced by adding serum) revealed significant differential 
lncRNAs dysregulations, indicating the potential roles of lncRNAs in regulating GSCs maintenance and 
differentiation. For example, Araki et al. examined the lncRNA expression profiles between GSCs 
derived from four different GBM patient samples and the corresponding differentiated tumor cells, and 
identified a set of 34 differentially expressed lncRNA transcripts (out of 2448, fold change ≥2.0) [47]. 
Amongst these, the most notable candidate is H19, which was one of most up-regulated lncRNAs in 
GSCs as compared to the differentiated cells, suggesting that H19 may have a potential role in stemness 
maintenance in GSCs. In support of this hypothesis, H19 has been reported as a crucial factor for the 
maintenance of adult haematopoietic stem cells [48]. 
A subsequent study that compared the gene expression patterns between GSCs and differentiated  
cells also observed dramatic lncRNA dysregulations. Aldaz et al. performed lncRNA profiling in four 
patient-derived GSCs (also defined by sphere formation) and the corresponding differentiated tumor 
cells. This revealed differential expressions of 39 lncRNAs (fold change ≥2.0) [42]. The study confirmed 
the up-regulation of H19 in GSCs, and also identified a large population of novel dysregulated lncRNA 
candidates. The most striking dysregulations were observed for MIAT, XIST, RP11-346D6.6, C6orf155 
and HCG4. Amongst these, MIAT and XIST were found to be up-regulated in GSCs when compared to 
differentiated cells; RP11-346D6.6, C6orf155 and HCG4 were down-regulated. Consistent with these 
findings, the up-regulation of XIST was confirmed in another study, in which XIST was found to have 
higher expression in GSCs and may regulate the GSCs growth both in vitro and in vivo [25]. 
However, it is important to note that there was little overlap between the lists of dysregulated 
lncRNAs from the above two studies; the degree of between-study concordance was low. For example, 
amongst the 34 lncRNAs identified in Araki’s study [47] and the 39 in Aldaz’s study [42], only  
four lncRNAs were identified in both studies, including the above mentioned H19. The similar situation 
was previously reported in miRNA profiling studies in glioma also [49]. The large variability in patient 
samples, as well as discrepancies in the choice of GSCs-maintaining medium may underlie this disparity. 
3.2. Dysregulated LncRNAs between GSCs with Different Subtypes 
LncRNAs are also differentially expressed in different subtypes of GSCs. It has been reported  
that GSCs may have different sub-phenotypes and thus growth properties [40,41]. For example, GSCs 
with positive CD133 expression showed a spherical growth pattern (non-adherent) in vitro and would 
form highly invasive tumors in vivo, while GSCs with negative CD133 expression demonstrated a  
semi-adherent (or adherent growth) in culture and reduced tumor invasion in animals [40,41].  
Comparative analysis of lncRNA profiles between these two subtypes of GSCs revealed significantly 
dysregulated lncRNAs, which may provide clues for the molecular mechanisms that underlie the  
differences in their growth phenotypes. For example, by comparing the lncRNA profiles of three  
CD133 + GSCs and three CD133 − GSCs, Beier et al. identified a set of 72 differentially expressed 
lncRNA transcripts (fold change ≥2.0) [40]. Among these, the expression levels of XIST, H19, and  
HOTAIR were markedly higher in the CD133 + GSCs than in the CD133− ones; while the expression 
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levels of CTC-231O11.1, RP11-745C15.2, LOC100130776, and C14orf139 were significantly lower in 
the CD133 + GSCs than in the CD133− ones (Table 1). Of these, the up-regulations of H19 and  
HOTAIR were confirmed by an independent subsequent study [41]. In support of this hypothesis, H19 
and HOTAIR have been reported to increase the propensities for tumor metastasis in bladder cancer and 
breast cancer [50–52]. 
3.3. Dysregulated LncRNAs between GSCs and Neural Stem Cells (NSCs) 
GSCs have similar but not identical characteristics to that in non-malignant NSCs [53–57]. The  
two cell types share some surface markers, can both divide and give rise to daughter stem cells with 
capabilities identical to that of the parental cells (self-renewal), and can both differentiate into multiple 
neural cell types (multipotency) [53–57]. However, unlike NSCs, GSCs act in a dysregulated manner and 
possess tumorigenic characters when implanted into immune-deficient animals [55]. By comparative 
analysis of lncRNA expression profiles between GSCs and non-malignant NSCs, Rheinbay et al. 
revealed the significantly differential expression for HOTAIRM1, H19, MALAT1 and SOX2ot [58]. 
The dramatic up-regulations of their expressions in GSCs indicate their potential oncogenic roles in the 
malignant transformation of NSCs. In agreement with this hypothesis, H19, MALAT1 and SOX2ot have 
been reported to be tumorigenic or to function as metastasis promoters in multiple cancer  
types [50,59–62]. 
4. Functional Roles and Molecular Mechanism of LncRNAs in GSCs 
While the significant lncRNA dysregulations observed above would suggest their potential  
roles in GSCs, the precise functions and molecular mechanism by which these lncRNAs may operate 
remain incompletely understood. There is currently little evidence to directly link these lncRNAs  
with specific cellular processes or signaling pathways in GSCs. However, it has been generally accepted 
that lncRNAs may function through interactions with their molecular partners, such as proteins and 
RNAs [19,63,64]. Therefore, analyzing the binding potentials of lncRNAs with their interactive 
molecules may theoretically help predict the formers’ functions and mechanisms. 
To decipher the functional roles of lncRNAs in GSCs, we have examined extensively the interactive 
potentials of various identified lncRNAs with transcription factors (TFs), RNA binding proteins (RBPs) 
and miRNAs, by using currently available research tools [65,66]. It is indeed interesting to find that 
lncRNAs may show strong binding potentials with some key transcription factors, miRNAs or gene 
pathways that are also crucial for the “stemness” maintenance in GSCs. A discussion of these findings 
from bioinformatics analyses by means of publicly available tools [65,66], and with a relevant literature 
review, is provided in the following sections and in Figure 2. Related interactive transcription factors, 
miRNAs and RNA binding proteins are summarized in Table 2. 
4.1. Interaction with Stem Cell Transcription Factors (TFs) 
Several transcription factors, such as c-Myc, OCT-4 and Nanog, have been shown to play key roles 
in promoting and stabilizing the “stem-cell-like” phenotype of non-malignant stem cells and  
GSCs [67–74]. These factors may activate the expression of a large number of downstream genes, 
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enhance self-renewal, and inhibit the differentiation of stem cells through various pathways [67–74]. The 
lncRNA-TF interaction analysis, based on the ChIP-Seq data, revealed numerous binding sites for key 
transcription factors in the promoter areas (5 kb upstream and 1 kb downstream) of these lncRNAs, 
implying that lncRNAs may act as mediators of these key transcription factors in regulating GSCs 
maintenance. 
 
Figure 2. Representative figures of lncRNA interaction with key molecules or cellular  
processes in GSCs. 
Table 2. Interaction of lncRNAs with TFs, miRNAs and RBPs 1. 
LncRNAs 2 Interactive TFs 3 (Number of Binding Sites) Interactive miRNAs 3 Interactive RBPs 3 
H19 NFKB (39), E2F (30), c-Myc (45), CTCF (60) 
miR-29a, miR-29b, miR-29c, miR-18a, miR-19a, 
miR-20a, miR-19b, et al. 
NA 
MIAT 
NFKB (45), E2F (43), Nanog (27),  
SMAD (20), c-Myc (15), Oct-4 (5), CTCF (20) 
miR-29a, miR-29b, miR-29c, and miR-150 NA 
XIST 
NFKB (18), TAF1 (14), c-Myc (8), CTCF (8), 
Nanog (2), HNF4A(6) 
miR-124, miR-34a, miR-137, miR-146a, miR-326, 
miR-7 and miR-425, miR-152, let-7, et al. 
LIN28, IGF2BP 
LOC100127888 NA NA NA 
RP11-112J3.16 HNF4A (1) NA NA 
LOC643763 CTCF (3), c-Myc (1), NFKB (1), Nanog (1) NA NA 
RP11-346D6.6 CDX2(2), GATA6 (3), HNF4A (3), Nanog (1) NA NA 
FLJ39609 CDX2(2), c-Myc (1), USF-1 (4) NA NA 
C6orf155 
CDX2(5), E2F (10), HNF4A (4),  
Nanog (5), SMAD (5) 
NA NA 
HCG4 NA NA NA 
DLX6-AS NA NA NA 
Abbreviations: TF, transcription factor; RBP, RNA binding protein; NA, not applicable. 1 The interactions of 
lncRNAs with miRNAs and RBPs were analyzed by using the public tool starbase v2.0 [Ref.65], and the 
interactions with TFs were analyzed by using the public tool ChIPBase [66]. Due to space limit. 2 Only 
lncRNAs indicated for GSCs maintenance (dysregulated in GSCs and differentiated GBM cells comparison) 
were enrolled for analysis here. 3 Only molecules that have been functionally reported in stemness regulation 
were included in the table. 
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An example is MIAT, which is one of the most highly upregulated lncRNAs in GSCs as compared 
to the differentiated GBM counterparts in Aldaz’s study [42]. By screening its promoter area, enriched 
binding sites were found for all the above three TFs: 27 binding sites for Nanog, 15 for c-Myc and 5 for 
OCT-4 (Table 2). While the functional role of MIAT in GSCs is not known, MIAT has been reported to 
interact with OCT-4 and may play regulatory roles in mouse embryonic stem cells [75]. Moreover, 
MIAT has been found to be dysregulated during the differentiation of normal neural stem cells [76].  
Its strong interaction with multiple key stem-cell-associated transcription factors and its significant 
dysregulation in GSCs suggest that MIAT may play important roles in regulating GSCs, and warrants 
further studies. 
Another interesting example is H19, which was one of the most up-regulated lncRNAs in GSCs as 
compared to differentiated GBM cells in the two aforementioned studies [42,47]. H19 was found to 
possess 45 c-Myc binding sites in its promoter area. As the first reported lncRNA in mammalian  
cells, H19 has been extensively studied in developmental biology as well as oncology during the past 
two decades [77,78]. Supporting our observation here, Barsyte et al. have shown that c-Myc could 
significantly induce the expression of H19 in T98G GBM cells through direct binding [79]. Although 
the tentative link between H19 and GSCs is yet to be confirmed, H19 has been found to regulate stemness 
in haematopoietic as well as embryonic stem cells [48,80]. How H19 may interact with c-Myc and regulate 
GSCs growth properties deserves further investigations. 
A significant lncRNA-TF interaction was also observed for another stem-cell-associated  
transcription factor, CTCT. CTCF (CCCTC-binding factor) is a highly conserved multifunctional  
DNA-binding protein with thousands of binding sites at the genome-wide level [81]. It can act as a 
transcriptional activator, repressor and insulator. It can also attract many other transcription factors, 
transcription activators or repressors to chromatin, and can thus play extensive regulatory roles in gene 
expressions [81,82]. CTCF is associated with some biological processes, including embryonic stem cell 
differentiation [83], neuronal [84] and haematopoietic development [85,86]. Here, we found that multiple 
lncRNAs, including H19, MIAT, XIST and LOC643763, contained abundant binding sites with CTCF 
(Table 2), suggesting the potential roles of CTCF in maintaining GSCs. Of even greater importance are 
XIST and H19, which contain 20 and 60 CTCF binding sites, respectively. It is therefore an attractive 
idea to investigate whether and how these lncRNAs would interact with CTCF and play regulatory roles 
in GSCs. In supporting our observation here, CTCF has actually been reported to mediate the imprinted 
expression of H19, as well as its neighbor gene IGF2 by means of methylation-dependent binding [87]. 
4.2. Interaction with MiRNAs 
GSCs-associated lncRNAs also contained enriched binding sites with miRNAs that have been 
reported to be functional in GSCs, suggesting that interaction with miRNA may be another potential 
functional entity of lncRNAs in GSCs. It has been suggested that lncRNAs and miRNAs might 
participate in a shared competing endogenous RNA (ceRNA) regulatory network, since they may 
actually regulate each other reciprocally [88,89]. In this ceRNA network, miRNA can regulate lncRNAs 
as they do on mRNAs since lncRNAs also have similar miRNA targeting sites as mRNAs as shown in 
a recent global analysis of Argonaute (Ago)-bound transcripts using the HITS-CLIP technique [65,90]. 
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At the same time, lncRNA can reversely regulate miRNAs through their abilities to compete for miRNA 
binding, and to act as miRNA sponge or host gene [91–93]. 
A notable example of lncRNA-miRNA interaction is XIST. This lncRNA was found to possess 
binding sites with almost all the well-characterized GSCs-associated miRNAs, suggestive of its potential 
role as a super “miRNA sponge”. These include miR-124, 34a, miR-137, miR-146a, miR-326, miR-7 
and miR-425 (Table 2). All these miRNAs are down-regulated in GSCs, and may regulate GSCs growth 
behavior by targeting different downstream targets [35,94]. Additionally, XIST also demonstrates 
binding potentials with other multiple miRNAs, which have previously not been functionally identified 
in GSCs. These include miR-152 and let-7 family members. This is in agreement with a recent study, 
which demonstrated a reciprocal regulation between XIST and miR-152 in GSCs [25]. In this interesting 
study, the authors first determined that XIST was up-regulated in GSCs, and that the knock-down of 
XIST would suppress GSCs growth in vitro and tumorigenicity in vivo. Further analyses revealed that 
there was reciprocal repression between XIST and miR-152: knock-down of XIST may up-regulate miR-
152, and vice versa [25]. The study provided the earliest evidence of lncRNA-miRNA interactions in 
GSCs. As for the let-7 family, it has been reported to regulate tumorigenicity in breast cancer stem cells 
[95]. The enriched binding targets existed for almost all the let-7 family members in XIST (let-7a, b, c, 
d, e, f, g). Together with other evidence (detailed in 4.3 below), these findings suggested that XIST may 
be another potential target in GSCs regulating. 
Significant lncRNA-miRNA interactions have also been observed for MIAT and H19 (Table 2). Both 
may act as the targets for miR-29 family (a, b, c), which has been widely reported to regulate cell 
proliferation, migration, invasion and tumorigenesis in GBM [42,96,97]. Additionally, H19 was found 
to possess targeting sites for multiple members of the miR-17-92 cluster. The latter has previously been 
implicated in the regulation of GBM neurosphere formation (presumably stem cells), differentiation, 
apoptosis and proliferation [98]. Inhibition of miR-17-92 reduced apoptosis and decreased cell 
proliferation in GBM neurospheres. These findings therefore indicated that H19-miR-17-92 cluster 
interaction may be one of possible ways in mediating the GSCs maintenance and differentiation. 
4.3. Interaction with NFKB Pathways 
The presence of extensive direct binding sites for NFKB or other key member genes in NFKB suggest 
the potential involvement of lncRNAs in this important signaling pathway. NFKB is a transcription 
factor and an inducer of signal pathway in glioma [99]. NFKB has been reported to regulate GSCs 
maintenance independently or in conjunction with the STAT and Notch pathways [100,101]. It was 
found that MIAT has 45 binding sites with NFKB in its promoter area, suggesting the involvement of 
NFKB and MIAT in each other’s signaling pathway. Another piece of supporting evidence for there 
being a connection between MIAT with NFKB pathway is their interactions with miR-29. As mentioned 
above, MIAT has enriched target sites for miR-29. It is interesting to found that miR-29 is also an 
important mediator of NFKB. NFKB could suppress miR-29 transcription and promoter function. It is 
thus tempting to speculate whether NFKB, miR-29 and MIAT may interact. 
Another lncRNA that showed interactions with NFKB is, again, XIST. The direct evidence is  
that XIST possess 18 NFKB binding sites in its promoter area. The indirect evidence is that XIST  
may interact with LIN28, a key member of NFKB pathway [102]. LIN28 is a conserved RNA-binding  
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protein (RBP) implicated for pluripotency, reprogramming, and oncogenesis [103–106]. It was 
previously shown that Lin28 expression could be activated directly by NFKB [102]. At the same time, 
LIN28 was able to decrease let-7 miRNA levels [102,107–109], and as well as the other downstream 
effects, such as the activation of STAT3 transcription factor [110]. This NFKB-LIN28-let-7 axis has 
been reported to be able to transform immortalized breast cells into self-renewing mammospheres that 
contain CSCs [102]. The interactions of XIST with NFKB, LIN28 and let-7 family mentioned above 
indicate the possible roles of XIST in maintaining GSCs properties through this axis. The detailed 
interactive mechanisms of XIST in this axis, however, need to be further studied. 
4.4. Interaction with Other Molecules or Pathways 
LncRNAs also has the tendency to interact with other well-characterized molecules or important 
cellular processes in GSCs. A detailed description is beyond the scope of this review. To cite an  
example, MIAT has been shown to be involved in TGF-beta signaling, since the former has 20 binding 
sites for the key signal transducer gene of the latter pathway-SMAD [111–113]. Three lncRNAs, 
including RP11-346D6.6, FLJ39609 and C6orf155, possess enriched binding sites with CDX2, 
indicating the potential interactions of lncRNAs in CDX2-mediated cellular processes crucial for the 
pluripotency maintenance [114]. Another three lncRNAs, C6orf155, MIAT and H19, also showed strong 
interactions with the cell-cycle gene E2F, an important family of transcription factors that regulate cell 
cycle progression and thus cell proliferation [115–117]. 
5. Conclusions 
Growing evidence has shown that GSCs, which possess resistance to radiation therapy and 
chemotherapy, are responsible for tumor initiation and propagation in GBM. These characteristics 
indicate that GSCs are promising therapeutic targets, and that eliminating GSCs may improve patient 
outcome. Successful targeted therapies depend heavily on the identification of unique markers and 
signaling pathways in GSCs that can distinguish them from both normal and the non-GSC tumor cells. 
The functional significance of lncRNAs in GBM and other cancer types is beginning to emerge. The 
identification of lncRNAs that are dysregulated in GSCs, as well as their potential functional 
mechanisms, will present researchers with many opportunities for the studying of GBM initiation and 
progression as well as the development of future treatment for glioma. Further researches are needed to 
identify and verify the functions of different lncRNAs in not only GBM but also other cancers. 
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